Breast Pfizer-C4891001
VERITAC-2- Open-Label Trial of ARV-471 (PF-07850327) vs. Fulvestrant in PTS W/ ER-Positive, HER2-Negative Advanced Breast Cancer w/ Disease Progression After Prior Endocrine Rx For Advanced Disease
Breast, A011801
CompassHer2 Residual Disease (RD): Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Breast, A191901
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions- "Get Set"
Breast, Ascent 03
Trodelvy vs MD Choice for Untreated PD-L1 Negative mTNBC or PD-L1 Positive Previously Treated w/ Anti PD-L1 Therapy Who Recur
Breast, CELC-G-301
Viktoria-1 Gedatolisib in Combination with Palbociclib and Fulvestrant Compared to SOC in Previously Treated Pts with HR-Positive, HER2 Negative Advanced Breast Cancer
Breast, EA1181
CompassHer2-pCR-Preoperative THP and Postoperative HP in Patients who Achieve a Pathologic Complete Response
Breast, NRG-BR007
DEBRA-De-escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18
Breast, TOL2506A
Ovarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA)